An adenosine dose producing AVB is required to unmask dormant PV conduction. AVB is significantly reduced in patients >110 kg. Weight and dosing variability may in part explain the conflicting results of studies evaluating the clinical utility of adenosine in PVI.

The model is most sensitive to the probability of a patient requiring an initial ablation, followed by redo ablation, but remains cost-saving for most variables. Conclusion: RFM is cost-effective and should be utilised by physicians managing AF. patients.